Cyberonics gains US OK for new VNS therapy (vagus nerve stimulation):
This article was originally published in Clinica
Cyberonics has gained US go-ahead to market a new line of implantable pacemaker-like devices for treating epilepsy. The new family includes a model 102 generator that is 33% thinner, 34% lighter and has 43% less volume than its predecessor, the model 101 generator, says the Texas, Houston firm. It also incorporates the model 302 lead, which is a single pin lead and which will be easier and faster to implant than its dual pin predecessor, the model 300 lead. Cyberonics' technology treats epilepsy using vagus nerve stimulation therapy (VNS).
You may also be interested in...
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.